However, to determine how intrinsic and acquired resistance to EGFR inhibitors in cancer treatments can be avoided, it is essential to comprehensively elucidate the regulatory landscape of the ERBB family and the interaction and crosstalk between lncRNAs and ERBB-family members. This evidence concerns the gene EGFR and cancer.